Dan Dearborn - 18 Oct 2024 Form 4 Insider Report for Kintara Therapeutics, Inc. (HURA)

Role
Chief Financial Officer
Signature
/s/ Dan Dearborn
Issuer symbol
HURA
Transactions as of
18 Oct 2024
Net transactions value
$0
Form type
4
Filing time
22 Oct 2024, 20:01:03 UTC
Next filing
14 Nov 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KTRA Options (Right to Buy) Award $0 +33,991 $0.000000 33,991 18 Oct 2024 Common Stock 33,991 $2.24 Direct F1
transaction KTRA Options (Right to Buy) Award $0 +68,438 $0.000000 68,438 18 Oct 2024 Common Stock 68,438 $2.24 Direct F1
transaction KTRA Options (Right to Buy) Award $0 +232,570 $0.000000 232,570 18 Oct 2024 Common Stock 232,570 $3.69 Direct F1, F2
transaction KTRA Options (Right to Buy) Award $0 +15,744 $0.000000 15,744 18 Oct 2024 Common Stock 15,744 $3.69 Direct F1, F3
transaction KTRA Options (Right to Buy) Award $0 +66,658 $0.000000 66,658 18 Oct 2024 Common Stock 66,658 $4.14 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."
F2 One-third of the stock options become exercisable on the first, second, and third anniversary of November 15, 2023.
F3 One-third of the stock options become exercisable on the first, second, and third anniversary of April 7, 2023.
F4 One-third of the stock options become exercisable on the first, second, and third anniversary of February 28, 2024.